依洛比昔巴特治疗老年慢性便秘患者的临床疗效。
Efficacy of elobixibat for elderly patients with chronic constipation in a clinic.
作者信息
Sakai Yuji, Tsuyuguchi Toshio, Kumagai Junichiro, Ohyama Hiroshi, Kaiho Takashi, Ohtsuka Masayuki, Kato Naoya
机构信息
Department of Gastroenterology, Sakai Clinic, Kimistu 299-1162, Japan.
Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
出版信息
World J Gastrointest Pharmacol Ther. 2025 Jun 5;16(2):105801. doi: 10.4292/wjgpt.v16.i2.105801.
BACKGROUND
Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined.
AIM
To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic.
METHODS
A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration.
RESULTS
In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status ( < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%).
CONCLUSION
Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.
背景
据报道，埃洛昔巴特可改善慢性便秘患者的排便情况。然而，其在临床环境中对老年慢性便秘患者排便情况的影响尚未得到研究。
目的
在我们诊所检查埃洛昔巴特给药前后老年慢性便秘患者的排便频率和粪便形态。
方法
对35名（<65岁）和45名（≥65岁）慢性便秘患者给予10毫克埃洛昔巴特。在埃洛昔巴特给药前后1周，比较两组患者使用布里斯托粪便形态量表（BSFS）评估的排便频率和粪便形态。
结果
在<65岁的慢性便秘患者中，埃洛昔巴特给药前的排便频率和BSFS评分分别为2.167±0.732和2.286±0.742。埃洛昔巴特给药后，排便频率和BSFS评分分别提高到2.389±0.502和3.995±0.566，排便情况有显著改善。在≥65岁的慢性便秘患者中，埃洛昔巴特给药前的排便频率和BSFS评分分别为2.003±0.733和2.217±0.758。埃洛昔巴特给药后，排便频率和BSFS评分分别提高到4.402±1.346和3.800±0.704，表明排便情况有所改善（<0.001）。≥65岁和<65岁的慢性便秘患者在排便频率、改善情况或BSFS评分方面未观察到显著差异。埃洛昔巴特给药导致的不良事件发生16例（20%）。<65岁（8例，22.9%）和≥65岁（8例，17.8%）的慢性便秘患者不良事件发生率无显著差异。
结论
埃洛昔巴特对改善慢性便秘患者的排便情况有效。<65岁和≥65岁的慢性便秘患者在排便情况改善或不良事件发生率方面未发现显著差异，表明该药物可安全用于老年患者。
Zotero 插件